Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 26;10(4):e2020102.
doi: 10.5826/dpc.1004a102. eCollection 2020 Oct.

Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab

Aline Lissa Okita  1 , Tatiane Benini  1 , Denise Reis Longhi  1
Affiliations

Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab

Aline Lissa Okita et al. Dermatol Pract Concept. .
No abstract available

Keywords: adalimumab; biologics; secukinumab; severe psoriasis; ustekinumab.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Clinical presentation prior to ustekinumab treatment.
Figure 2
Figure 2
Clinical presentation. (A) After adalimumab treatment. (B) After 5 weeks of secukinumab treatment.
Figure 3
Figure 3
Clinical presentation. (A) After adalimumab treatment. (B) After 5 weeks of secukinumab treatment.
See this image and copyright information in PMC

References

    1. Morgado-Carrasco D, Riera-Monroig J, Fustà-Novell X, Alsina Gibert M. Response to secukinumab after treatment failure with ustekinumab in 6 patients with plaque psoriasis. Actas Dermosifiliogr. 2018;109(6):565–567. doi: 10.1016/j.ad.2017.07.019. - DOI - PubMed
    1. Warren RB, Barker J, Burden AD, et al. Secukinumab has demonstrated efficacy and safety in hard-to-treat anti–tumor necrosis factor α failure patients from the United Kingdom and Republic of Ireland: Results of the SIGNATURE study. J Am Acad Dermatol. 2018;79(3 Suppl 1):AB256. doi: 10.1016/j.jaad.2018.05.1018. Poster Abstract. - DOI
    1. Magnano M, Loi C, Patrizi A, et al. Secukinumab in multi-failure psoriatic patients: the last hope? J Dermatolog, Treat. 2018;29(6):583–585. doi: 10.1080/09546634.2018.1427206. - DOI - PubMed
    1. Pelechas E, Memi T, Voulgari PV, Drosos AA. A case of recalcitrant psoriatic arthritis to tnf inhibitors improved after administration of secukinumab, an IL-17A inhibitor. Rheumatol Ther. 2017;4(2):509–513. doi: 10.1007/s40744-017-0084-0. - DOI - PMC - PubMed

LinkOut - more resources